Login to Your Account

$49M Series C Round

Immune Design Moving Cancer Immunotherapy Platform into Clinic

By Jennifer Boggs
Managing Editor

Wednesday, October 30, 2013

As further proof that cancer immunotherapy is no longer the biopharma pariah of several years ago, Immune Design Corp. closed a $49 million Series C round to advance its lead candidates into the clinic.

The financing, which nearly doubles the Seattle-based biotech’s $52 million venture capital to date, includes $32.5 million up front, with the remaining $16.5 million anticipated after the firm gathers Phase I data, said President and CEO Carlos Paya. Immune Design aims to move into the clinic next year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription